Download
s40618-021-01600-w.pdf 571,73KB
WeightNameValue
1000 Titel
  • Role of thyroid hormone therapy in depressive disorders
1000 Autor/in
  1. Bauer, Michael |
  2. Whybrow, P. C. |
1000 Erscheinungsjahr 2021
1000 Publikationstyp
  1. Artikel |
1000 Online veröffentlicht
  • 2021-06-15
1000 Erschienen in
1000 Quellenangabe
  • 44(11):2341-2347
1000 Copyrightjahr
  • 2021
1000 Lizenz
1000 Verlagsversion
  • https://doi.org/10.1007/s40618-021-01600-w |
  • https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8502157/ |
1000 Publikationsstatus
1000 Sprache der Publikation
1000 Abstract/Summary
  • Purpose!#!The close association among thyroid metabolism, mood disorders and behavior has long been known. The old and modern uses of thyroid hormones to modulate the expression of depression and bipolar disorder and to improve clinical outcome when used in conjunction with psychotropic medications.!##!Methods!#!A literature search was performed to identify studies investigating the effects of thyroid hormone treatment in patient s with mood disorders.!##!Results!#!The successful modification of mood disorders with thyroid hormone underscores the association between endocrine and cerebral systems in these disorders. Thyroid hormones have a profound influence on behavior and appear to be capable of modulating the phenotypic expression of major mood disorders. In fact, there is evidence that triiodothyronine (LT3) may accelerate the antidepressant response to antidepressants, and studies suggest that LT3 also may augment the response to antidepressants in refractory depression. Add-on treatment with supraphysiologic doses of levothyroxine (LT4) has shown efficacy in open-label and in placebo-controlled studies, including in rapid cycling and prophylaxis-resistant bipolar disorder, and with acute refractory uni- or bipolar depression. Functional brain-imaging studies (PET) demonstrated that administration of supraphysiologic LT4 improves depressive symptoms in patients with bipolar depression by modulating cerebral activity in the anterior limbic network.!##!Conclusion!#!The add-on administration of supraphysiologic doses of LT4 is a promising strategy in patients with refractory bipolar and depressive mood disorders.
1000 Sacherschließung
lokal Depressive Disorder/drug therapy [MeSH]
lokal Major depression
lokal Humans [MeSH]
lokal Levothyroxine
lokal Thyroid Hormones/metabolism [MeSH]
lokal Triiodothyronine
lokal Bipolar disorder
lokal Depressive Disorder/metabolism [MeSH]
lokal Thyroid Diseases/metabolism [MeSH]
lokal Bipolar Disorder/drug therapy [MeSH]
lokal Thyroxine/pharmacology [MeSH]
lokal Thyroid hormone treatment
lokal Short Review
lokal Drug Interactions [MeSH]
lokal Thyroid Diseases/psychology [MeSH]
lokal Antidepressive Agents/pharmacology [MeSH]
lokal Bipolar Disorder/metabolism [MeSH]
lokal Thyroid Hormones/pharmacology [MeSH]
1000 Liste der Beteiligten
  1. https://orcid.org/0000-0002-2666-859X|https://frl.publisso.de/adhoc/uri/V2h5YnJvdywgUC4gQy4=
1000 Hinweis
  • DeepGreen-ID: 030663b323bd481da1732b70c5a3dfad ; metadata provieded by: DeepGreen (https://www.oa-deepgreen.de/api/v1/), LIVIVO search scope life sciences (http://z3950.zbmed.de:6210/livivo), Crossref Unified Resource API (https://api.crossref.org/swagger-ui/index.html), to.science.api (https://frl.publisso.de/), ZDB JSON-API (beta) (https://zeitschriftendatenbank.de/api/), lobid - Dateninfrastruktur für Bibliotheken (https://lobid.org/resources/search)
1000 Label
1000 Dateien
  1. Role of thyroid hormone therapy in depressive disorders
1000 Objektart article
1000 Beschrieben durch
1000 @id frl:6445348.rdf
1000 Erstellt am 2023-04-28T10:02:15.064+0200
1000 Erstellt von 322
1000 beschreibt frl:6445348
1000 Zuletzt bearbeitet 2023-10-20T15:15:17.515+0200
1000 Objekt bearb. Fri Oct 20 15:15:17 CEST 2023
1000 Vgl. frl:6445348
1000 Oai Id
  1. oai:frl.publisso.de:frl:6445348 |
1000 Sichtbarkeit Metadaten public
1000 Sichtbarkeit Daten public
1000 Gegenstand von

View source